Boehringer, Gubra stop work on obesity drug; Galapagos restarts CAR-T study

Plus, news about Alnylam, Hutchmed, Wave Life Sciences and Matinas BioPharma:

Boehringer Ingelheim ends work with Gubra on obesity drug: The German drugmaker

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Showdown at Masimo: Proxy battle targets CEO Kiani’s leadership, board

Masimo Chairman and CEO Joe Kiani is about to face his toughest challenge yet as leader of the patient monitoring company he founded more than

June 23, 2023

Menopause myths: Separating fact from fiction

Many women approach menopause with anxiety about the future. You’ve probably heard your grandmother, mother, or aunts lament about menopause, aka “the change,” as a

August 6, 2024

More patients are losing their doctors — and trust in the primary care system

First, her favorite doctor in Providence, Rhode Island, retired. Then her other doctor at a health center a few miles away left the practice.

April 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.